2022-501414-53-00招募中2 期
MODAFIMS: An open-label, single-center clinical trial to evaluate predictors of response to MODAFinil in the treatment of cognitive deficits in patients with Multiple Sclerosis
CCAB Centro Clinico Academico Braga Associacao1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2024年6月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Changes in brain function and connectivity measured using resting state fMRI (at baseline and after 3 months of treatment with Modafinil). Functional MRI will be performed at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit).
研究概览
简要总结
- Identification of acute resting-state fMRI features that differentiate between responders and non-responders to modafinil at baseline.
- Identification of long-term resting-sate fMRI features that differentiate between responders and non-responders to modafinil after 3 months of treatment with modafinil.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Participant is willing and able to give informed consent for the participation in the trial
- •Participants, that in the medical investigator’s opinion, are able and willing to comply with all trial requirements.
- •Patients that are able to read and write
- •Male or female, aged between 18 and 64 years old at the time of signing the ICF
- •Diagnosed with Relapsing-Remitting MS or Clinically Isolated Syndrome, according to McDonald 2017 diagnostic criteria (Thompson et al., 2018).
- •Expanded disability status score (EDSS) less than 6.
- •Presence of subjective cognitive complaints
- •SDMT score (number of correct responses within 90 seconds) at Screening ≤ 55 (Benedict et al., 2016; Parmenter et al., 2007).
- •Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner use protocol’s recommended effective contraception methods, which is not based only on hormonal methods, during all the 6 months of the trial (3 months of treatment plus 3 months of safety follow-up).
- •Male participants must agree to refrain from donation of semen from first study treatment administration up to at least 90 days after last administration.
排除标准
- •Female participant who is pregnant, breastfeeding or planning pregnancy during the trial.
- •Positive test for anti-Human Immunodeficiency virus 1 or 2 antibodies, Hepatitis B surface antigen (HBsAg) or anti Hepatitis C virus antibodies.
- •Creatinine clearance < 20 ml/min determined by Cockcroft-Gault equation.
- •Participants who have participated in another research trial involving an investigational product within the past 5 half-lives of the other investigational product
- •History of alcoholism or drug abuse.
- •Average daily consumption of more than 20 cigarettes.
- •Participants with disability that interferes with the performance of the CT procedures (for example, motor deficit in upper limb, decreased visual acuity even with correction).
- •Participants with increased risk of epileptic seizures, history of cardiac arrhythmias, or uncontrolled moderate to severe hypertension.
- •Participants taking warfarin or any other prohibited medication.
- •Any other condition that, in the opinion of the investigator, contra-indicates the participation of the patient.
- •Participants who have any disability that, in the opinion of the investigator, significantly interferes with the neuropsychological testing and/or the tasks in the functional MRI
- •Significant neurological history aside from MS (e.g., Epilepsy).
- •Participants not able to undergo MRI scanning
- •Participants who have any contra-indication for taking modafinil, according to the prescribing information and SmPC, such as hypersensitivity to the active substance and any excipient present in the modafinil or any documented adverse reaction after modafinil intake
- •Participants with known hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- •Participants with a history of left ventricular hypertrophy or cor pulmonale and patients with mitral valve prolapse who developed mitral valve prolapse syndrome when previously treated with central nervous system stimulants
- •Current use of modafinil, armodafinil
- •Current use of other psychostimulants, including amphetamines, cocaine, bupropion, gingko biloba, among others, and beverages or food containing methylxanthines (e.g., coffee, tea, cola, caffeine, chocolate, sodas) exceeding 500 mg methylxanthines per day (for example, consumption of more than 5 espresso coffees or 100 mg of dark chocolate per day; Sanchez, 2017).
- •Sleep complaints confirmed by Epworth Sleepiness Scale (ESS) scale score >10 at screening visit OR known sleep disorder.
- •Significant psychiatric history (e.g., Schizophrenia, Bipolar Disorder, Major Depression, severe anxiety disorder, aggressive or hostile behaviour).
- •A documented history of attempted suicide in the last 2 years OR suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in the assessment of suicidal ideation on the C-SSRS) over the 6 months prior to the Screening Visit.
- •Significant insomnia (grade > 1 according to Common Terminology Criteria for Adverse Events, CTCAE v5).
- •History of severe hypersensitivity reactions to any medicine
- •Presence of any clinically significant abnormality in ECG morphology or ECG parameters
- •Known immunodeficiency syndrome
- •Have serum alanine aminotransferase (ALT) values greater than 3 times the upper limit of normal at screening
结局指标
主要结局
Changes in brain function and connectivity measured using resting state fMRI (at baseline and after 3 months of treatment with Modafinil). Functional MRI will be performed at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit).
Changes in brain function and connectivity measured using resting state fMRI (at baseline and after 3 months of treatment with Modafinil). Functional MRI will be performed at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit).
次要结局
- Changes in brain function and connectivity measured using a Go/no-Go task fMRI.
- Changes in patient reported outcomes (PROs) and neuropsychological tests - Perceived Deficits Questionnaire (PDQ), Symbol Digit Modalities Test (SDMT), Stroop test measured as interference index, MS-specific QoL questionnaire, Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS) and Modified Fatigue Impact Scale (MFIS). These assessments will occur in the screening or baseline visits and at the end of treatment (3-month visit).
研究者
Clinical Project Manager
Scientific
CCAB Centro Clinico Academico Braga Associacao
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)2023-503251-10-00Medica Scientia Innovation Research S.L.60
招募中
2 期
Venglustat in Combination with Cerezyme in Adult Patients with Gaucher Disease Type 3 with
venglustat monotherapy extension2023-508646-18-00Genzyme Corp.3
尚未招募
2 期
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic TherapyNCT07277972Tianjin Medical University Cancer Institute and Hospital36
尚未招募
不适用
Pivotal U.S. Clinical Validation of AI-COA® for Depression and AnxietyAnxiety DisordersNCT07279038Deliberate Solutions Inc.650
招募中
3 期
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityObesityNCT07285902Fujian Shengdi Pharmaceutical Co., Ltd.750